These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 28109882)

  • 81. Minimal immune response to booster vaccination against Yellow Fever associated with pre-existing antibodies.
    Bovay A; Nassiri S; Maby-El Hajjami H; Marcos Mondéjar P; Akondy RS; Ahmed R; Lawson B; Speiser DE; Fuertes Marraco SA
    Vaccine; 2020 Feb; 38(9):2172-2182. PubMed ID: 32008879
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period.
    Tanizaki R; Ujiie M; Hori N; Kanagawa S; Kutsuna S; Takeshita N; Hayakawa K; Kato Y; Ohmagari N
    J Travel Med; 2016 Mar; 23(3):. PubMed ID: 27021495
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Yellow fever: a decade of reemergence.
    Robertson SE; Hull BP; Tomori O; Bele O; LeDuc JW; Esteves K
    JAMA; 1996 Oct; 276(14):1157-62. PubMed ID: 8827969
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Yellow fever vaccination: is one dose always enough?
    Patel D; Simons H
    Travel Med Infect Dis; 2013; 11(5):266-73. PubMed ID: 24074827
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Estimating the number of unvaccinated Chinese workers against yellow fever in Angola.
    Wilder-Smith A; Massad E
    BMC Infect Dis; 2018 Apr; 18(1):185. PubMed ID: 29665797
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Yellow fever risk assessment in the Central African Republic.
    Ramos Junior AN; Heukelbach J
    Trans R Soc Trop Med Hyg; 2015 Apr; 109(4):231-2. PubMed ID: 25732754
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Yellow fever virus: historical and current issues regarding recent epidemics and vaccination in Brazil.
    Ishak R; de Oliveira Guimarães Ishak M; Vallinoto ACR; De Paula Pinheiro F
    Hum Vaccin Immunother; 2020 Apr; 16(4):900-903. PubMed ID: 31634051
    [TBL] [Abstract][Full Text] [Related]  

  • 88. International travel between global urban centres vulnerable to yellow fever transmission.
    Brent SE; Watts A; Cetron M; German M; Kraemer MU; Bogoch II; Brady OJ; Hay SI; Creatore MI; Khan K
    Bull World Health Organ; 2018 May; 96(5):343-354B. PubMed ID: 29875519
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Yellow fever control: current epidemiology and vaccination strategies.
    Chen LH; Wilson ME
    Trop Dis Travel Med Vaccines; 2020; 6():1. PubMed ID: 31938550
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Yellow fever in Africa and South America, 2007.
    Wkly Epidemiol Rec; 2009 Mar; 84(13):97-104. PubMed ID: 19326583
    [No Abstract]   [Full Text] [Related]  

  • 91. Yellow Fever: Origin, Epidemiology, Preventive Strategies and Future Prospects.
    Gianchecchi E; Cianchi V; Torelli A; Montomoli E
    Vaccines (Basel); 2022 Feb; 10(3):. PubMed ID: 35335004
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Trends of major disease outbreaks in the African region, 2003-2007.
    Kebede S; Duales S; Yokouide A; Alemu W
    East Afr J Public Health; 2010 Mar; 7(1):20-9. PubMed ID: 21413568
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Infectious disease. Resurgence of yellow fever in Africa prompts a counterattack.
    Roberts L
    Science; 2007 May; 316(5828):1109. PubMed ID: 17525307
    [No Abstract]   [Full Text] [Related]  

  • 95. Fractional-dose yellow fever vaccination: how much more can we do with less?
    Visser LG
    Curr Opin Infect Dis; 2019 Oct; 32(5):390-393. PubMed ID: 31335440
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Community knowledge, attitudes and practices on Yellow fever in South Omo area, Southern Ethiopia.
    Legesse M; Endale A; Erku W; Tilahun G; Medhin G
    PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006409. PubMed ID: 29630594
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.
    Monath TP; Nichols R; Archambault WT; Moore L; Marchesani R; Tian J; Shope RE; Thomas N; Schrader R; Furby D; Bedford P
    Am J Trop Med Hyg; 2002 May; 66(5):533-41. PubMed ID: 12201587
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Single shot of 17D vaccine may not confer life-long protection against yellow fever.
    Vasconcelos PF
    Mem Inst Oswaldo Cruz; 2018 Feb; 113(2):135-137. PubMed ID: 29185596
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Japanese encephalitis virus/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice.
    Yang H; Yang H; Li Z; Liu L; Wang W; He T; Fan F; Sun Y; Liu J; Li Y; Zeng X
    Vaccine; 2018 Apr; 36(18):2450-2455. PubMed ID: 29580643
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Safety of the yellow Fever vaccine: a retrospective study.
    Nordin JD; Parker ED; Vazquez-Benitez G; Kharbanda EO; Naleway A; Marcy SM; Molitor B; Kuckler L; Baggs J
    J Travel Med; 2013; 20(6):368-73. PubMed ID: 24118538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.